Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Other Non Operating Income: 2023-2025

Historic Other Non Operating Income for Tonix Pharmaceuticals Holding (TNXP) over the last 2 years, with Sep 2025 value amounting to -$1.2 million.

  • Tonix Pharmaceuticals Holding's Other Non Operating Income fell 2527.27% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.7 million, marking a year-over-year decrease of 441.26%. This contributed to the annual value of -$2.1 million for FY2024, which is 220.73% down from last year.
  • Per Tonix Pharmaceuticals Holding's latest filing, its Other Non Operating Income stood at -$1.2 million for Q3 2025, which was up 40.87% from -$2.0 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's 5-year Other Non Operating Income high stood at $172,000 for Q3 2023, and its period low was -$2.1 million during Q1 2025.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's median Other Non Operating Income value was -$606,000 (recorded in 2024), while the average stood at -$861,556.
  • Data for Tonix Pharmaceuticals Holding's Other Non Operating Income shows a maximum YoY plummeted of 21,342.86% (in 2024) over the last 5 years.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's Other Non Operating Income (Quarterly) stood at $7,000 in 2023, then plummeted by 21,342.86% to -$1.5 million in 2024, then plummeted by 2,527.27% to -$1.2 million in 2025.
  • Its Other Non Operating Income stands at -$1.2 million for Q3 2025, versus -$2.0 million for Q2 2025 and -$2.1 million for Q1 2025.